In 2015, RVNC conducted an unsuccessful phase-2 trial in hyperhidrosis using the (now discontinued) topical toxin formulation called RT001 (#msg-119391369).
Hyperhidrosis is a fairly small indication for Botox, so I don’t think RVNC should spend money seeking FDA approval of Daxi in hyperhidrosis; even without hyperhidrosis in the FDA label, Daxi will get some off-label business.
News 
Market Data 
Discover 
